Sanofi Company Profile (NYSE:SNY)

About Sanofi (NYSE:SNY)

Sanofi logoSanofi is a healthcare company, focused on patient needs and engaged in the research, development, manufacture and marketing of therapeutic solutions. The Company's segments are Pharmaceuticals, Human Vaccines (Vaccines), and Other. The Pharmaceuticals segment comprises the commercial operations of various franchises, including Speciality Care (Rare Diseases, Multiple Sclerosis, and Oncology), Diabetes and Cardiovascular, Established Prescription Products, Consumer Healthcare and Generics, and research and development, production and marketing activities for all of the Company's pharmaceuticals operations. The Vaccines segment is dedicated to vaccines and includes the commercial operations of the Company's vaccines division Sanofi Pasteur and dedicated research and development, production and marketing activities for the Company's vaccines operations. Its Rare Diseases products include Cerezyme, Cerdelga, Myozyme and Lumizyme, Fabrazyme, and Aldurazyme.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Pharmaceuticals
  • Sub-Industry: N/A
  • Symbol: NYSE:SNY
  • CUSIP: N/A
  • Web:
  • Market Cap: $126.43 billion
  • Outstanding Shares: 2,511,508,000
Average Prices:
  • 50 Day Moving Avg: $48.38
  • 200 Day Moving Avg: $47.45
  • 52 Week Range: $36.81 - $50.65
  • Trailing P/E Ratio: 11.69
  • Foreward P/E Ratio: 14.47
  • P/E Growth: 1.95
Sales & Book Value:
  • Annual Revenue: $43.62 billion
  • Price / Sales: 2.90
  • Book Value: $27.57 per share
  • Price / Book: 1.83
  • Annual Dividend: $1.10
  • Dividend Yield: 3.3%
  • EBIDTA: $13.09 billion
  • Net Margins: 25.89%
  • Return on Equity: 25.34%
  • Return on Assets: 14.17%
  • Debt-to-Equity Ratio: 0.26%
  • Current Ratio: 1.59%
  • Quick Ratio: 1.16%
  • Average Volume: 1.23 million shs.
  • Beta: 0.88
  • Short Ratio: 1.35

Frequently Asked Questions for Sanofi (NYSE:SNY)

What is Sanofi's stock symbol?

Sanofi trades on the New York Stock Exchange (NYSE) under the ticker symbol "SNY."

How often does Sanofi pay dividends? What is the dividend yield for Sanofi?

Sanofi announced an annual dividend on Friday, February 17th. Stockholders of record on Monday, May 15th will be given a dividend of $1.5771 per share on Wednesday, June 7th. This represents a dividend yield of 3.65%. The ex-dividend date of this dividend is Thursday, May 11th. This is a positive change from Sanofi's previous annual dividend of $1.10. View Sanofi's Dividend History.

How were Sanofi's earnings last quarter?

Sanofi (NYSE:SNY) released its quarterly earnings data on Monday, July, 31st. The company reported $0.74 EPS for the quarter, hitting the Zacks' consensus estimate of $0.74. The business had revenue of $8.66 billion for the quarter, compared to analysts' expectations of $8.71 billion. Sanofi had a net margin of 25.89% and a return on equity of 25.34%. Sanofi's quarterly revenue was down 2.3% on a year-over-year basis. View Sanofi's Earnings History.

When will Sanofi make its next earnings announcement?

Sanofi is scheduled to release their next quarterly earnings announcement on Friday, October, 27th 2017. View Earnings Estimates for Sanofi.

Where is Sanofi's stock going? Where will Sanofi's stock price be in 2017?

11 brokers have issued 12-month target prices for Sanofi's shares. Their predictions range from $52.00 to $55.00. On average, they expect Sanofi's stock price to reach $53.50 in the next twelve months. View Analyst Ratings for Sanofi.

What are analysts saying about Sanofi stock?

Here are some recent quotes from research analysts about Sanofi stock:

  • 1. Argus analysts commented, "The company also has a strong new drug pipeline that includes Toujeo, a next-generation insulin product, and dipilumab, for atopic dermatitis and other inflammatory conditions," the analyst said.See also: Where Does Zika Virus Vaccine Research Stand Now? FY18 ExpectationsArgus expects the company's 2017 revenues from continuing operations to benefit from the recent acquisition of Boehringer Ingelheim's consumer health business and higher sales of multiple sclerosis products. At the same time, the firm expects reduced diabetes drug sales.The firm also sees margin pressure due to pricing pressures for diabetes products in the U.S. and costs related to the launch of Dupixent and Kevzara, partly offset by a sales force reorganization and other cost-savings initiatives."In 2018, we expect continued solid demand for multiple sclerosis drugs and increased sales in emerging markets to outweigh weaker sales of diabetes drugs, and look for the company's cost-savings program to benefit margins," (9/1/2017)
  • 2. According to Zacks Investment Research, "Sanofi possesses a diversified product portfolio with a presence in several therapeutic areas. Sanofi’s focus on streamlining its business and pursuing business development deals is encouraging. Sanofi has several new products in its portfolio and candidates in its pipeline that can contribute to long-term growth. New drugs like Aubagio and Lemtrada are likely to continue doing well.  We are also optimistic on sales prospects of Dupixent, which could prove to be an important growth driver. The recent FDA approval of Kevzara for rheumatoid arthritis is also encouraging. Sanofi’s shares have outperformed the large-cap pharma industry this year so far. However, headwinds include a bleak outlook for the Diabetes franchise, generic competition for many drugs and slower-than-expected uptake of new products like Praluent. At the Q1 conference call, management warned that the US diabetes sales will decline faster through 2017." (6/2/2017)

Who are some of Sanofi's key competitors?

Who are Sanofi's key executives?

Sanofi's management team includes the folowing people:

  • Serge Weinberg, Independent Chairman of the Board
  • Olivier Brandicourt, Chairman of the Executive Committee, Chief Executive Officer, Director
  • Jerome Contamine, Executive Vice President, Chief Financial Officer, Member of the Executive Committee and the Senior Leadership Team
  • Karen Marie Linehan, Executive Vice President, Legal Affairs and General Counsel, Member of the Executive Committee and the Senior Leadership Team
  • Olivier Charmeil, Executive Vice President and General Manager, General Medicines & Emerging Markets, Member of the Executive Committee and the Senior Leadership Team
  • Peter Guenter, Executive Vice President and General Manager, Diabetes & Cardiovascular, Member of the Executive Committee and the Senior Leadership Team
  • Carsten Hellmann, Executive Vice President and General Manager of Merial, Member of the Executive Committee and the Senior Leadership Team
  • David Loew, Executive Vice President and General Manager of Sanofi Pasteur, Member of the Executive Committee and the Senior Leadership Team
  • David P. Meeker M.D., Executive Vice President and General Manager of Sanofi Genzyme, Member of the Executive Committee and the Senior Leadership Team
  • Roberto Pucci, Executive Vice President, Human Resources, Member of the Executive Committee and the Senior Leadership Team

Who owns Sanofi stock?

Sanofi's stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include Dodge & Cox (2.50%), Franklin Resources Inc. (0.83%), Fisher Asset Management LLC (0.54%), Boston Partners (0.32%), Hotchkis & Wiley Capital Management LLC (0.23%) and FMR LLC (0.21%). View Institutional Ownership Trends for Sanofi.

Who sold Sanofi stock? Who is selling Sanofi stock?

Sanofi's stock was sold by a variety of institutional investors in the last quarter, including Dodge & Cox, Hotchkis & Wiley Capital Management LLC, Wells Fargo & Company MN, Federated Investors Inc. PA, Boston Partners, Macquarie Group Ltd., Northern Trust Corp and Tekla Capital Management LLC. View Insider Buying and Selling for Sanofi.

Who bought Sanofi stock? Who is buying Sanofi stock?

Sanofi's stock was acquired by a variety of institutional investors in the last quarter, including Southpoint Capital Advisors LP, Fisher Asset Management LLC, BlackRock Inc., Janus Henderson Group PLC, FMR LLC, Harbour Capital Advisors LLC, Aperio Group LLC and Schafer Cullen Capital Management Inc.. View Insider Buying and Selling for Sanofi.

How do I buy Sanofi stock?

Shares of Sanofi can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Sanofi's stock price today?

One share of Sanofi stock can currently be purchased for approximately $50.34.

MarketBeat Community Rating for Sanofi (NYSE SNY)
Community Ranking:  2.2 out of 5 (star star)
Outperform Votes:  228 (Vote Outperform)
Underperform Votes:  284 (Vote Underperform)
Total Votes:  512
MarketBeat's community ratings are surveys of what our community members think about Sanofi and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Sanofi (NYSE:SNY) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 1 Sell Rating, 6 Hold Ratings, 4 Buy Ratings
Consensus Rating:Hold (Score: 2.27)
Consensus Price Target: $53.50 (6.28% upside)

Analysts' Ratings History for Sanofi (NYSE:SNY)
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
9/15/2017J P Morgan Chase & CoReiterated RatingNeutralLowView Rating Details
9/1/2017ArgusReiterated RatingBuy$55.00MediumView Rating Details
8/30/2017HSBC Holdings plcUpgradeReduce -> HoldMediumView Rating Details
8/1/2017Cowen and CompanyReiterated RatingMarket Perform$46.00 -> $52.00LowView Rating Details
5/11/2017Berenberg BankDowngradeBuy -> HoldLowView Rating Details
3/9/2017Liberum CapitalInitiated CoverageHold -> HoldLowView Rating Details
3/7/2017Barclays PLCInitiated CoverageUnderweightN/AView Rating Details
2/9/2017NatixisUpgradeNeutral -> BuyN/AView Rating Details
1/10/2017Leerink SwannReiterated RatingOutperformN/AView Rating Details
1/8/2017Goldman Sachs Group, Inc. (The)Reiterated RatingHoldN/AView Rating Details
11/29/2016Morgan StanleyUpgradeEqual Weight -> OverweightN/AView Rating Details
9/23/2016Piper Jaffray CompaniesInitiated CoverageNeutralN/AView Rating Details
9/14/2016Jefferies Group LLCReiterated RatingHoldN/AView Rating Details
9/13/2016BNP ParibasUpgradeUnderperform -> NeutralN/AView Rating Details
6/28/2016Citigroup Inc.Reiterated RatingNeutralN/AView Rating Details
5/3/2016Bank of America CorporationReiterated RatingBuy$58.00N/AView Rating Details
4/12/2016Chardan CapitalReiterated RatingBuyN/AView Rating Details
2/10/2016Sanford C. BernsteinLower Price TargetMarket-Perform$52.00 -> $45.00N/AView Rating Details
12/16/2015Oddo SecuritiesDowngradeReduceN/AView Rating Details
11/9/2015Bryan, Garnier & CoReiterated RatingBuy -> NeutralN/AView Rating Details
(Data available from 9/25/2015 forward)


Earnings History for Sanofi (NYSE:SNY)
Earnings by Quarter for Sanofi (NYSE:SNY)
Earnings History by Quarter for Sanofi (NYSE SNY)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
7/31/20176/30/2017$0.74$0.74$8.71 billion$8.66 billionViewN/AView Earnings Details
4/28/20173/31/2017$0.73$0.76$8.40 billion$8.65 billionViewN/AView Earnings Details
2/8/2017Q416$0.66$0.67$9.87 billion$8.88 billionViewN/AView Earnings Details
10/29/2015Q315$0.88$0.89$10.97 billion$10.67 billionViewN/AView Earnings Details
4/30/2015Q115$0.61$0.73$9.21 billion$9.78 billionViewN/AView Earnings Details
2/5/2015Q4$0.89$0.79$11.34 billion$10.39 billionViewN/AView Earnings Details
7/31/2014Q2$0.79$0.72$11.19 billion$10.82 billionViewN/AView Earnings Details
4/29/2014Q114$0.84$0.81$11.19 billion$10.88 billionViewN/AView Earnings Details
2/6/2014Q4$0.88$0.93ViewN/AView Earnings Details
10/30/2013$1.01$0.93ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Sanofi (NYSE:SNY)
2017 EPS Consensus Estimate: $3.21
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20172$0.75$0.78$0.77
Q2 20171$0.74$0.74$0.74
Q3 20171$0.90$0.90$0.90
Q4 20171$0.80$0.80$0.80
(Data provided by Zacks Investment Research)


Current Dividend Information for Sanofi (NYSE:SNY)
Most Recent Dividend:6/7/2017
Annual Dividend:$1.10
Dividend Yield:2.19%
Dividend Growth:-2.50% (3 Year Average)
Payout Ratio:28.06% (Trailing 12 Months of Earnings)
33.03% (Based on This Year's Estimates)
31.61% (Based on Next Year's Estimates)
Dividend Payments by Quarter for Sanofi (NYSE:SNY)

Dividend History by Quarter for Sanofi (NYSE SNY)
AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Insider Trading and Institutional Ownership History for Sanofi (NYSE:SNY)
Insider Ownership Percentage: 1.00%
Institutional Ownership Percentage: 9.33%
Insider Trades by Quarter for Sanofi (NYSE:SNY)
Institutional Ownership by Quarter for Sanofi (NYSE:SNY)
Insider Trades by Quarter for Sanofi (NYSE:SNY)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
8/24/2017SanofiMajor ShareholderBuy105,820$482.04$51,009,472.80View SEC Filing  
8/23/2017SanofiMajor ShareholderBuy60,595$478.98$29,023,793.10View SEC Filing  
7/9/2014SanofiMajor ShareholderBuy195,000$308.27$60,112,650.00View SEC Filing  
7/8/2014SanofiMajor ShareholderBuy153,000$311.67$47,685,510.00View SEC Filing  
(Data available from 1/1/2013 forward)


Headline Trends for Sanofi (NYSE:SNY)
Latest Headlines for Sanofi (NYSE:SNY)
DateHeadline logoIs Sanofi (SNY) a Great Stock for Value Investors? - September 23 at 7:40 AM logoSanofi (SNY) Presents At Bank of America Merrill Lynch 2017 Global Healthcare Conference - Slideshow - September 19 at 7:55 AM logoAceto Corporation (ACET) and Sanofi (SNY) Head to Head Survey - September 18 at 6:40 PM logoSanofi: Sanofi and Regeneron Announce Positive Study Results for Dupixent® (dupilumab) in Patients With Moderate-to-Severe Atopic Dermatitis - September 17 at 8:03 AM logoJ P Morgan Chase & Co Reaffirms Neutral Rating for Sanofi SA (SNY) - September 15 at 2:34 PM logoSanofi Reports Results Of TAKE CONTROL Study - Quick Facts - Nasdaq - September 14 at 10:26 AM logoSanofi (SNY) Says New Post-hoc Analysis Shows Soliqua 100/33 Provided Earlier Blood Sugar Control than Insulin ... - - September 14 at 10:26 AM logoReviewing Sanofi (SNY) & Eyegate Pharmaceuticals (EYEG) - September 14 at 12:26 AM logoRegeneron/Sanofi's Dupixent Asthma Study Meets Endpoints - September 12 at 10:01 AM logoSanofi Reports Post-hoc Analysis Of Phase 3 Soliqua 100/33 Trials - September 12 at 10:01 AM logoFeatured Company News - Regeneron Pharma and Sanofi's Cemiplimab Receives Breakthrough Therapy Designation from US FDA - September 12 at 10:01 AM logoMinerva Neurosciences Names Dr. Jay Saoud as Senior Vice President, Head of Research and Development - September 11 at 9:23 AM logoSanofi, Regeneron: Dupilumab Hits Main Objectives in Late-Stage Asthma Trial - September 11 at 2:58 AM logoSanofi (SNY) Receives Consensus Rating of "Hold" from Brokerages - September 9 at 6:45 PM logoRegeneron and Sanofi's cemiplimab a Breakthrough Therapy for type of skin cancer - September 9 at 8:40 AM logo[$$] Sanofi Stops Work on Two Zika Vaccines - September 9 at 8:40 AM logoRegeneron (REGN) & Sanofi (SNY) Granted FDA Breakthrough Designation for Cemiplimab (REGN2810), Advanced ... - - September 8 at 8:34 AM logoSanofi: Sanofi Alliance Partner Alnylam Gives Update on Fitusiran - September 7 at 9:12 AM logoSanofi Has Good Potential Upside - September 7 at 9:12 AM logoSanofi Alliance Partner Alnylam Gives Update on Fitusiran - September 7 at 8:20 AM logoSanofi stops work on Zika vaccines - September 7 at 3:04 AM logoSanofi rated AA by Scope Ratings - September 7 at 2:40 AM logoFDA tentatively OKs Sanofi's fast-acting insulin Admelog; shares up 1%; Lilly down 2% - September 2 at 8:54 AM logoSanofi (SNY) Reports Tentative FDA Approval of Admelog 100 Units/mL - September 2 at 8:54 AM logoSanofi (SNY) Rating Reiterated by Argus - September 1 at 8:20 PM logoSanofi (SNY) Upgraded to "Hold" by HSBC Holdings plc - August 30 at 7:32 PM logoFinancial Review: Sanofi (SNY) & Johnson & Johnson (JNJ) - August 29 at 10:28 PM logo3 Healthcare Stocks to Buy With Dividends Yielding More Than 3% - August 29 at 8:08 AM logoSanofi: Sanofi completes the acquisition of Protein Sciences - August 28 at 6:35 AM logoSanofi completes the acquisition of Protein Sciences - August 28 at 2:40 AM logoInsider Buying: Sanofi (SNY) Major Shareholder Buys 60,595 Shares of Stock - August 25 at 7:22 PM logoSanofi (SNY) Major Shareholder Sanofi Buys 105,820 Shares - August 25 at 7:22 PM logoJanuvia and Janument: An Update on Merck’s Diabetes Franchise after 2Q17 - August 25 at 11:51 AM logoCan Sanofi (SNY) Sustain the Solid 1H Momentum in 2H17? - August 24 at 12:59 PM logoCoLucid Pharmaceuticals (CLCD) versus Sanofi (SNY) Critical Review - August 21 at 6:16 PM logoSanofi Genzyme Continues Driving Revenue Growth in 2Q17 - August 18 at 7:21 AM logoEuropean Pharma Companies Slip on MS Pricing Probe - August 18 at 7:21 AM logoSen. Grassley says Mylan's $465 million Epi-Pen settlement 'shortchanges' taxpayers - August 17 at 6:17 PM logoEpiPen maker settles: It'll pay less than what it got by allegedly overcharging - August 17 at 5:27 PM logoETFs with exposure to Sanofi : August 16, 2017 - August 17 at 7:46 AM logoSanofi’s Revenue Growth in 2Q17 - August 17 at 7:46 AM logoSanofi (SNY) Given Consensus Recommendation of "Hold" by Analysts - August 15 at 10:46 PM logoSanofi's Zika Standoff: Bad Medicine? - Seeking Alpha - August 11 at 8:40 AM logoSanofi (SNY) Sues to Defend its Patent Rights on Lantus - - August 9 at 7:40 AM logoSanofi (SNY) Sues to Defend its Patent Rights on Lantus - - August 9 at 7:40 AM logoDupixent Asthma Data Could Seal A Second Blockbuster Market - Seeking Alpha - August 9 at 7:40 AM logoDupixent Asthma Data Could Seal A Second Blockbuster Market - Seeking Alpha - August 9 at 7:40 AM logoThis Week's Pharma, Energy IPOs - August 8 at 6:59 AM logoSanofi (SNY) Upgraded by BidaskClub to Hold - August 5 at 5:30 PM logoRegeneron to terminate antibody discovery partnership with Sanofi at year-end - Seeking Alpha - August 4 at 8:22 AM



Sanofi (SNY) Chart for Monday, September, 25, 2017

This page was last updated on 9/25/2017 by Staff